All tyrosine kinase inhibitor articles
-
ArticleM&A outlook for pharma in 2025
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.